<!doctype html>
<html class="no-js" lang="en">

<head>
  <!-- Global site tag (gtag.js) - Google Analytics -->
  <script async src="https://www.googletagmanager.com/gtag/js?id=UA-134228602-13"></script>
  <script>
    window.dataLayer = window.dataLayer || [];
    function gtag(){dataLayer.push(arguments);}
    gtag('js', new Date());

    gtag('config', 'UA-134228602-13');
  </script>

  <meta charset="utf-8">
  <meta http-equiv="x-ua-compatible" content="ie=edge">
  <title>👆🏻 👩🏿‍🤝‍👨🏻 🔆 Wedge by wedge: use of the PIV5 virus to create a vaccine against MERS-CoV and possibly against SARS-CoV-2 ✋🏿 🔊 🏜️</title>
  <link rel="icon" type="image/x-icon" href="/favicon.ico" />
  <meta name="description" content="Given the current circumstances, it is not at all surprising that the scientific community has concentrated all its forces on the search and developme...">
  <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">

  <link rel="stylesheet" href="../../css/main.css">

  <link href="https://fonts.googleapis.com/css?family=Quicksand&display=swap" rel="stylesheet">

  <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.3.1/jquery.min.js"></script>
  <script>window.jQuery || document.write('<script src="../../js/vendors/jquery-3.3.1.min.js"><\/script>')</script>

  <script>document.write('<script src="//pagea' + 'd2.googles' + 'yndication.com/pagea' + 'd/js/a' + 'dsby' + 'google.js"><\/script>')</script>
  <script>
        var superSpecialObject = {};
        superSpecialObject['google_a' + 'd_client'] = 'ca-p' + 'ub-6974184241884155';
        superSpecialObject['enable_page_level_a' + 'ds'] = true;
       (window['a' + 'dsbygoogle'] = window['a' + 'dsbygoogle'] || []).push(superSpecialObject);
  </script>
</head>

<body>
  <!--[if lte IE 9]>
    <p class="browserupgrade">You are using an <strong>outdated</strong> browser. Please <a href="https://browsehappy.com/">upgrade your browser</a> to improve your experience and security.</p>
  <![endif]-->
  <header class="page-header js-page-header">
    <a class="page-header-logo-container" href="https://geek-week.github.io/index.html"></a>
    <div class="page-header-text">Get best of the week</div>
  </header>
  <section class="page js-page"><h1>Wedge by wedge: use of the PIV5 virus to create a vaccine against MERS-CoV and possibly against SARS-CoV-2</h1><div class="post__body post__body_full">
      <div class="post__text post__text-html post__text_v1" id="post-content-body" data-io-article-url="https://habr.com/ru/company/ua-hosting/blog/497144/"><img src="https://habrastorage.org/webt/rw/tp/5v/rwtp5vcu3hrcxqugrvpuxhkakkk.jpeg"><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
Given the current circumstances, it is not at all surprising that the scientific community has concentrated all its forces on the search and development of methods and tools to combat the spreading virus. </font><font style="vertical-align: inherit;">Today we look at a study in which scientists from the American Society for Microbiology (ASM) describe a very working vaccine against the MERS virus, which began to spread in 2012. </font><font style="vertical-align: inherit;">According to scientists, their development can help create a vaccine against the currently raging SARS-CoV-2. </font><font style="vertical-align: inherit;">What is the peculiarity of the created vaccine, from which it was created, and how effectively does it perform its task? </font><font style="vertical-align: inherit;">We learn about this from the report of scientists. </font><font style="vertical-align: inherit;">Go.</font></font><br>
<a name="habracut"></a><br>
<blockquote><img src="https://habrastorage.org/webt/fi/0x/4z/fi0x4z2nhcc3-3bdzugakb4csji.png" align="left"><h2><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">UFO Care Minute</font></font></h2><br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
The pandemic COVID-19, a potentially severe acute respiratory infection caused by the SARS-CoV-2 coronavirus (2019-nCoV), has officially been announced in the world. </font><font style="vertical-align: inherit;">There is a lot of information on Habré on this topic - always remember that it can be both reliable / useful, and vice versa.</font></font><br>
<br>
<h4><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">We urge you to be critical of any published information.</font></font></h4><br>
<div class="spoiler" role="button" tabindex="0">
                        <b class="spoiler_title"><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">Official sources</font></font></b>
                        <div class="spoiler_text"><ul>
<li><a href="https://translate.googleusercontent.com/translate_c?depth=1&amp;pto=aue&amp;rurl=translate.google.com&amp;sl=ru&amp;sp=nmt4&amp;tl=en&amp;u=">C   </a></li>
<li><a href="https://translate.googleusercontent.com/translate_c?depth=1&amp;pto=aue&amp;rurl=translate.google.com&amp;sl=ru&amp;sp=nmt4&amp;tl=en&amp;u=">C </a></li>
<li><a href="https://translate.googleusercontent.com/translate_c?depth=1&amp;pto=aue&amp;rurl=translate.google.com&amp;sl=ru&amp;sp=nmt4&amp;tl=en&amp;u=">  ()</a></li>
<li><a href="https://translate.googleusercontent.com/translate_c?depth=1&amp;pto=aue&amp;rurl=translate.google.com&amp;sl=ru&amp;sp=nmt4&amp;tl=en&amp;u="> </a></li>
<li>       </li>
</ul><br>
     ,      .</div>
                    </div><br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
Wash your hands, take care of your loved ones, stay at home whenever possible and work remotely. </font></font><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
Read publications about: </font></font><a href="https://translate.googleusercontent.com/translate_c?depth=1&amp;pto=aue&amp;rurl=translate.google.com&amp;sl=ru&amp;sp=nmt4&amp;tl=en&amp;u="><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">coronavirus</font></font></a><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> | </font></font><a href="https://translate.googleusercontent.com/translate_c?depth=1&amp;pto=aue&amp;rurl=translate.google.com&amp;sl=ru&amp;sp=nmt4&amp;tl=en&amp;u="><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">remote work</font></font></a></blockquote><br>
<h3><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">Study basis</font></font></h3><br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
MERS or the Middle East respiratory syndrome is an inflammatory disease of the respiratory organs that develops due to infection with the virus of the genus Betacoronavirus from the now familiar subfamily Coronavirinae. </font></font><br>
<br>
<img src="https://habrastorage.org/webt/my/wp/zx/mywpzxjvq7ea_c4nqfapnnbqxfi.jpeg"><br>
<i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">Snapshot of MERS-CoV (yellow).</font></font></i><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
The source of the MERS-CoV virus is again bats. The first cases of infection among people were recorded back in 2012 on the territory of the Arabian Peninsula, but by 2015 the virus had reached the countries of East Asia and Europe. According to the latest data, the number of confirmed cases of MERS-CoV infection is 2494 people, among whom 858 died (data from 02.02.2020). The data vary from source to source, but it is clearly seen that the degree of distribution in MERS-CoV is not as great as in SARS-CoV-2. Nevertheless, the Middle East virus also has a rather high mortality rate - about 35%. This indicator is the most worrying. </font></font><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
MERS-CoV is a </font></font><i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">positive chain RNA virus *</font></font></i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> , in which penetration into target cells is carried out due to the S-protein</font></font><i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">viral envelope *</font></font></i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> .</font></font><blockquote><b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">Positive chain RNA virus *</font></font></b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> - positive viral RNA. </font><font style="vertical-align: inherit;">This implies that a particular viral RNA sequence can be directly translated into viral proteins (e.g., proteins necessary for virus replication). </font><font style="vertical-align: inherit;">Therefore, in RNA viruses with a positive chain, the viral RNA gene can be considered viral mRNA (messenger RNA) and it can be immediately translated by the host cell.</font></font></blockquote><blockquote><b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">Viral envelope *</font></font></b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> - an additional envelope covering the outer envelope (capsid) of many viruses.</font></font></blockquote><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">The S protein consists of the S1 subunit responsible for binding to the virus receptor, dipeptidyl peptidase 4 (DPP4 or CD26) via the receptor binding domain (RBD from the </font></font><i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">receptor binding domain</font></font></i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> ), as well as the S2 subunit, which provides membrane fusion. </font></font><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
Researchers recall that at the moment there is no vaccine against MERS-CoV, there are only a number of developments whose effectiveness is quite doubtful. Scientists believe that their work will change this situation. </font></font><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
In this study, scientists decided to turn their attention to another virus - PIV5. PIV or parainfluenza viruses (PG) have five varieties, three of which cause diseases in humans (from PG-1 to PG-3) and two that are not dangerous for humans (PG-4 and PG-5). </font></font><br>
<br>
<img src="https://habrastorage.org/webt/cz/4c/z7/cz4cz7k7ob0qvnrec3lkenrjo0q.jpeg"><br>
<i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">TEM snapshot of parainfluenza virus.</font></font></i> <br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
PG-5 is a member of the genus Rubulavirus from the Paramyxoviridae family, which includes mumps virus (MuV or “mumps”) and human parainfluenza virus type 2 (PG-2) and type 4 (PG-4). </font><font style="vertical-align: inherit;">PG-5 encodes eight known viral proteins. </font><font style="vertical-align: inherit;">Nucleocapsid protein (NP), phosphoprotein (P) and RNA polymerase protein (L) are important for </font></font><i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">transcription *</font></font></i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> and </font></font><i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">replication *</font></font></i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> of the viral RNA genome.</font></font><blockquote><b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">Transcription *</font></font></b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> - the process of RNA synthesis using DNA as a template; </font><font style="vertical-align: inherit;">transfer of genetic information from DNA to RNA.</font></font></blockquote><blockquote><b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">Replication *</font></font></b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> is the process of creating two daughter DNA molecules based on parental DNA.</font></font></blockquote><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">Scientists believe that PG-5 is an excellent candidate for </font></font><i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">viral vectors *</font></font></i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> for the future vaccine. </font><font style="vertical-align: inherit;">PG-5 is quite safe, despite its high degree of infectiousness, which can play into the hands when creating an effective vaccine.</font></font><blockquote><b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">Viral vectors *</font></font></b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> are tools for delivering genetic material to target cells.</font></font></blockquote><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">In addition, PG-5 does not have a DNA phase in its life cycle, which avoids possible inadvertent genetic modifications of the host cell DNA by recombination or insertion. Also, the structure of PG-5 is quite stable, in contrast to RNA viruses with a positive chain. This is confirmed by the created recombinant PG-5 expressing the F gene for the respiratory syncytial virus, when the F gene was maintained for more than 10 generations. </font></font><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
Another advantage of PG-5 is its cost-effectiveness, as this virus can be grown up to 8x10 </font></font><sup><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">8</font></font></sup><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> PFU / ml (PFU - plaque forming units).</font></font><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
Previously, PG-5 was already used as a viral vector when working with vaccines against the respiratory syncytial virus and rabies. </font><font style="vertical-align: inherit;">During experiments in mice, it was found that the PG-5 vector expressing NA (neuraminidase, which is part of the membrane) of the influenza virus, leads to complete immunization of the experimental subjects, i.e. </font><font style="vertical-align: inherit;">4 days after infection, there was not a single case of death or even infection. </font><font style="vertical-align: inherit;">But PG-5, expressing NP (nucleoprotein), protects 100% of experimental mice from the lethal strain of the H1N1 influenza virus. </font></font><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
Based on such positive results from previous studies, scientists decided to use PG-5 as a viral vector expressing the MERS virus S protein. </font><font style="vertical-align: inherit;">As before, all experiments were carried out on mice.</font></font><br>
<br>
<h3><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">Research results</font></font></h3><br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
Researchers preliminarily introduced the HA (hemagglutinin) gene of the influenza A virus into different places in the PG-5 genome and found that inserts in SH (small hydrophobic) and HN (hemagglutinin-neuraminidase) give a better immune response.</font></font><blockquote><b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">Influenza virus hemagglutinin and neuraminidase *</font></font></b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> are surface antigens of the virus that provide the ability to attach to target cells.</font></font></blockquote><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">Given this, it was decided to introduce the full-sized S gene of the MERS virus at the intersection of SH and HN. </font></font><i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">A plasmid *</font></font></i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> containing a full-sized </font></font><i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">cDNA *</font></font></i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> PG-5 with an inserted S gene at the junction of SH and HN was constructed using standard molecular cloning methods ( </font></font><b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">1A</font></font></b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> ). </font></font><br>
<br>
<img src="https://habrastorage.org/webt/d7/56/yo/d756yoxsps9t47yfxwats2hyhso.jpeg"><br>
<i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">Image No. 1</font></font></i><blockquote><b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">Plasmid *</font></font></b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> is a small DNA molecule that is separated from chromosomes and capable of independent replication.</font></font></blockquote><blockquote><b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">cDNA *</font></font></b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> - complementary DNA, i.e. </font><font style="vertical-align: inherit;">DNA synthesized on a matrix of mature mRNA (messenger RNA) in a reaction catalyzed by reverse transcriptase.</font></font></blockquote><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">The plasmid was </font></font><i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">transfected *</font></font></i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> into </font></font><i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">BHK *</font></font></i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> cells along with plasmids expressing the TG, NP, P and L RNA polymerase of PG-5 virus (PIV5).</font></font><blockquote><b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">Transfection *</font></font></b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> - the introduction of nucleic acid into cells by a non-viral method.</font></font></blockquote><blockquote><b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">BHK cells *</font></font></b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> ( </font></font><i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">baby hamster kidney</font></font></i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> ) are connective tissue cells (fibroblast) of hamster kidneys that are sensitive to many viruses that affect humans. </font><font style="vertical-align: inherit;">BHK cells are used for transformation, as well as for stable and transient transfections.</font></font></blockquote><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">The result was the infectious virus PIV5-MERS-S, which was further purified and multiplied in large numbers in </font></font><i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">MDBK cells *</font></font></i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> for further analysis.</font></font><blockquote><b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">MDBK cells *</font></font></b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> ( </font></font><i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">Madin-Darby canine kidney cells</font></font></i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> ) - dog kidney cells, first isolated in 1958 by scientists SH Madin and NB Darby. </font><font style="vertical-align: inherit;">These cells are used in research as model mammalian cells.</font></font></blockquote><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">The virus genome was sequenced and confirmed that it contains the desired input DNA sequence. </font><font style="vertical-align: inherit;">Next, it was necessary to check the expression of S protein in cells infected with PIV5-MERS-S. </font><font style="vertical-align: inherit;">For this, the cells were infected at different </font></font><i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">MOI *</font></font></i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> values </font><font style="vertical-align: inherit;">, after which they were lysed (dissolved) for </font></font><i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">immunoblotting *</font></font></i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> using an anti-S antibody.</font></font><blockquote><b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">MOI *</font></font></b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> ( </font></font><i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">multiplicity of infection</font></font></i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> ) - the multiplicity of infection, i.e. </font><font style="vertical-align: inherit;">the ratio of agents (virus) to targets for infection (cells).</font></font></blockquote><blockquote><b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">Immunoblotting *</font></font></b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> is a highly sensitive method for detecting proteins, based on a combination of electrophoresis and enzyme immunoassay or radioimmune analysis.</font></font></blockquote><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">The analysis showed the presence of both full S protein and S2 fragments, which indicates the success of its implementation ( </font></font><b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">1B</font></font></b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> ). </font><font style="vertical-align: inherit;">S protein expression in PIV5-MERS-S infected cells was further confirmed by immunofluorescence analysis ( </font></font><b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">1C</font></font></b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> ). </font></font><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
Scientists note that PIV5-MERS-S caused massive </font></font><i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">syncytium *</font></font></i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> formation </font><font style="vertical-align: inherit;">in </font></font><i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">Vero *</font></font></i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> cells </font><font style="vertical-align: inherit;">. </font><font style="vertical-align: inherit;">In addition, the growth kinetics of PIV5-MERS-S and conventional PG-5 (PIV5) was very similar ( </font></font><b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">1D</font></font></b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> ).</font></font><blockquote><b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">Syncytium *</font></font></b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> is a type of tissue in which cells are not completely separated, i.e. </font><font style="vertical-align: inherit;">there are sections of cytoplasm with nuclei that are interconnected by plasmodesmata (cytoplasmic bridges).</font></font></blockquote><blockquote><b>Vero*</b> —     ,       .</blockquote><br>
<img src="https://habrastorage.org/webt/pv/4z/w_/pv4zw_vfg2sjgwdwftwze2psqpk.jpeg"><br>
<i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">Image No. 2</font></font></i><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> 
Immunization PIV5-MERS-S generates neutralizing antibodies and T-cell mediated immunity. To determine whether PIV5-MERS-S can generate immune responses, mice were immunized with a single dose of PIV5-MERS-S or control PIV5-GFP virus at 10 </font></font><sup><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">4</font></font></sup><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> PFU or 10 </font></font><sup><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">6</font></font></sup><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> PFU per individual via the intranasal pathway. </font></font><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
While both doses elicited antibody responses, neutralizing titers were modest at 1:64 and 1: 128 for 10 </font></font><sup><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">4</font></font></sup><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> and 10 </font></font><sup><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">6</font></font></sup><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> doses, respectively ( </font></font><b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">2A</font></font></b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> and </font></font><b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">2B</font></font></b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> ). </font></font><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
Scientists recall that mice of the species C57BL / 6 and BALB / c after immunization generate Th1- and Th2-dominant immune responses, respectively.</font></font><blockquote><b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">Th</font></font></b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> (T-helpers) - T-lymphocytes that enhance the adaptive immune response (acquired immunity). </font></font><br>
<br>
<b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">Th1</font></font></b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> - promote the development of a cellular immune response by activating macrophages. </font></font><br>
<br>
<b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">Th2</font></font></b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> - activate B-lymphocytes, which helps the development of a humoral immune response.</font></font></blockquote><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">One dose of PIV5-MERS-S (10 </font></font><sup><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">6</font></font></sup><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> PFU) resulted in a titer of neutralizing antibodies up to 1: 2000 in BALB / c ( </font></font><b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">2C</font></font></b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> ) </font><font style="vertical-align: inherit;">mice </font><font style="vertical-align: inherit;">, which is consistent with the Th2-dominant response in mice of this species. </font></font><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
To evaluate the primary response of </font></font><b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">CD8 *</font></font></b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> T cells generated by immunization with PIV5-MERS-S, hDPP4-KI mice were intranasally immunized with PIV5-MERS-S (10 </font></font><sup><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">4</font></font></sup><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> PFU).</font></font><blockquote><b>CD8*</b> (<i>  8</i>) —  ,    - .</blockquote><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">Four weeks later, a fence was taken to examine the presence / absence of MERS-CoV-specific pulmonary resident CD8 T cells ( </font></font><b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">3A</font></font></b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> ). </font></font><br>
<br>
<img src="https://habrastorage.org/webt/8v/nd/54/8vnd54kim9j1g4pb3hxyi39b-m0.jpeg"><br>
<i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">Image No. 3</font></font></i><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> 
As shown in </font></font><b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">3B</font></font></b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> - </font></font><b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">3D</font></font></b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> , there was a significant increase in the percentage and total number of CD8-IFN cells in the lungs of mice immunized with PIV5-MERS compared to those infected with PIV5-GFP. </font></font><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
To evaluate the response of MERS-S-specific CD8 T cells, an additional MERS-CoV </font></font><sub><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">MA</font></font></sub><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> injection was performed </font><font style="vertical-align: inherit;">(10 </font></font><sup><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">4</font></font></sup><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> PFU). As a result, a significant increase in the response of CD8 T cells on the fourth day was seen compared to mice infected with the control PIV5-GFP ( </font></font><b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">3E</font></font></b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> - </font></font><b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">3G</font></font></b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">) </font></font><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
A 10-fold increase in MERS-S-specific CD8 T cells was also observed compared to the primary response of CD8 T cells ( </font></font><b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">3B</font></font></b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> - </font></font><b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">3G</font></font></b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> ). </font></font><br>
<br>
<img src="https://habrastorage.org/webt/ew/ts/lh/ewtslh2j6vz9tnrb1hbwzsfbi9g.jpeg"><br>
<i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">Image No. 4</font></font></i><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> 
As a result of PIV5-MERS-S immunization prevents the death of infection in mice. To determine the effectiveness of PIV5-MERS-S in the prevention or modification of the MERS-CoV virus, hDPP4 KI mice were immunized with PIV5-MERS-S (10 </font></font><sup><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">4</font></font></sup><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> PFU) by the intranasal route. </font></font><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
4 weeks after immunization, the mice were infected with MERS-S modified to be more active in mice ( </font></font><b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">4A</font></font></b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> ). All mice immunized with PIV5-MERS-S survived this deadly infection, with slight weight loss ( </font></font><b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">4B</font></font></b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> and</font></font><b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">4C</font></font></b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> ). </font><font style="vertical-align: inherit;">In contrast, all mice infected with the control PIV5-GFP or PBS died after infection. </font><font style="vertical-align: inherit;">This indicates that PIV5-MERS-S fully protected mice from lethal infection. </font></font><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
Despite the fact that PIV5-MERS-S immunized mice had a higher rate of lung clearance from the virus, this method did not provide complete sterilizing immunity ( </font></font><b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">4D</font></font></b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> ). </font></font><br>
<br>
<img src="https://habrastorage.org/webt/50/tc/cs/50tccsxfzqipbqqma0q1jarkbjo.jpeg"><br>
<i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">Image No. 5</font></font></i><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> 
Histopathological studies of the lungs after infection showed that mice immunized with PIV5-MERS-S had significantly less </font></font><i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">cellular debris *</font></font></i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> and more mononuclear infiltrates ( </font></font><b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">5A</font></font></b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> and </font></font><b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">5B</font></font></b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> ).</font></font><blockquote><b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">Cell debris *</font></font></b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> is the remainder of the cell surrounded by a plasma membrane that is phagocytosed by macrophages.</font></font></blockquote><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">Strong leukocyte infiltration (mainly mononuclear cells) and less damage (edema, hyaline membranes, necrotic cell debris, etc.) were also detected. </font></font><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
At the final stage of the study, scientists evaluated the protective responses induced by PIV5-MERS-S or inactivated MERS-CoV. For this, some mice were immunized with PIV5-MERS-S (10 </font></font><sup><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">4</font></font></sup><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> PFU) or PBS, while others were immunized with UV-inactivated MERS-CoV. </font></font><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
While PIV5-MERS-S provided 100% protection against lethal infection, inactivated MERS-CoV protected only 25% of mice (image below). </font></font><br>
<br>
<img src="https://habrastorage.org/webt/xo/gm/fd/xogmfdg9rerwvmywjppp9rtufyy.jpeg"><br>
<i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">Image No. 6</font></font></i><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> 
Next, a study was carried out of the lungs of mice that were first immunized and then infected with MERS-CoV (image below). </font></font><br>
<br>
<img src="https://habrastorage.org/webt/pr/pi/ge/prpigenq6dw5crjetoqyjs_msym.jpeg"><br>
<i><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">Image No. 7</font></font></i><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
More eosinophils (a type of white blood cell) were observed in the lungs in mice immunized with inactivated MERS-CoV than in mice immunized with PBS or PIV5-MERS-S after infection with MERSCoV. </font></font><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
Compared to PBS, perivascular eosinophilic infiltration was significantly increased in the inactivated MERS-CoV group, but no statistical difference was observed compared to the group immunized with PIV5-MERS-S.</font></font><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
An assessment was also made of the formation of a hyaline membrane in the alveoli of the lungs, which is a clear sign of severe pulmonary disease. </font><font style="vertical-align: inherit;">Compared to the PBS group, mice immunized with PIV5-MERS-S showed significant protection against hyaline membrane formation. </font><font style="vertical-align: inherit;">But the mice immunized with inactivated MERS-CoV showed only a slight decrease in the formation of the hyaline membrane, which indicates the low efficiency of this method of immunization, in comparison with PIV5-MERS-S. </font></font><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
For a more detailed acquaintance with the nuances of the study, I recommend a look at the </font></font><a href="https://translate.googleusercontent.com/translate_c?depth=1&amp;pto=aue&amp;rurl=translate.google.com&amp;sl=ru&amp;sp=nmt4&amp;tl=en&amp;u="><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">report of scientists</font></font></a><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> .</font></font><br>
<br>
<h3><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">Epilogue</font></font></h3><br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
In this work, scientists were able to demonstrate a quite successful method of immunizing mice with the MERS-CoV virus, which has been walking freely on our planet since 2012. </font></font><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
The main distinguishing feature of the developed method is the use of another virus, namely PG-5, as a viral vector. In other words, the wedge is knocked out by wedge.</font></font><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
The use of the virus as a transport for the delivery of genes necessary for immunization can be considered a rather unusual method, but it can contribute to a more effective fight against viruses. The researchers themselves say that their work is aimed not only at combating MERS-CoV, but also with SARS-CoV-2 (COVID-19). Both viruses belong to the same subfamily, have similar infection pathways and effects on target cells. If the developed method of immunization is further developed, then it may be possible to create a sufficiently effective vaccine. </font></font><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
This is what the authors of this work are planning to do in the future. Whether they succeed in creating a super vaccine or not, time will tell. However, now they are worthy of all praise at least for paying attention to the virus, about which everyone seemed to forget.</font></font><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
Be that as it may, we can only hope that science and everyone involved, like many times before, will be able to overcome all prejudices and fears, overcome all obstacles and show that analytical thinking, based on knowledge and logic, is always capable of find a way out of any current situation, no matter how terrible at first glance it may be. </font></font><br>
<br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
Thank you for your attention, remain curious and have a good working week, guys.</font></font><br>
<br>
<h3><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">A bit of advertising :)</font></font></h3><br><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">
Thank you for staying with us. Do you like our articles? Want to see more interesting materials? Support us by placing an order or recommending to your friends </font></font><a href="https://translate.googleusercontent.com/translate_c?depth=1&amp;pto=aue&amp;rurl=translate.google.com&amp;sl=ru&amp;sp=nmt4&amp;tl=en&amp;u="><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">cloud-based VPS for developers from $ 4.99</font></font></a><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> , a </font></font><b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">unique analog of entry-level servers that was invented by us for you: </font></font></b> <a href="https://translate.googleusercontent.com/translate_c?depth=1&amp;pto=aue&amp;rurl=translate.google.com&amp;sl=ru&amp;sp=nmt4&amp;tl=en&amp;u="><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">The whole truth about VPS (KVM) E5-2697 v3 (6 Cores) 10GB DDR4 480GB SSD 1Gbps from $ 19 or how to divide the server?</font></font></a><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> (options are available with RAID1 and RAID10, up to 24 cores and up to 40GB DDR4). </font></font><br>
<br>
<b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">Dell R730xd 2 times cheaper at the Equinix Tier IV data center in Amsterdam?</font></font></b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> Only we have </font></font><b><a href="https://translate.googleusercontent.com/translate_c?depth=1&amp;pto=aue&amp;rurl=translate.google.com&amp;sl=ru&amp;sp=nmt4&amp;tl=en&amp;u="><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">2 x Intel TetraDeca-Core Xeon 2x E5-2697v3 2.6GHz 14C 64GB DDR4 4x960GB SSD 1Gbps 100 TV from $ 199</font></font></a><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> in the Netherlands!</font></font><b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">Dell R420 - 2x E5-2430 2.2Ghz 6C 128GB DDR3 2x960GB SSD 1Gbps 100TB - from $ 99! </font></font></b></b><font style="vertical-align: inherit;"><font style="vertical-align: inherit;">Read about</font></font><a href="https://translate.googleusercontent.com/translate_c?depth=1&amp;pto=aue&amp;rurl=translate.google.com&amp;sl=ru&amp;sp=nmt4&amp;tl=en&amp;u="><font style="vertical-align: inherit;"><font style="vertical-align: inherit;"> How to Build Infrastructure Bldg. </font><font style="vertical-align: inherit;">class c using Dell R730xd E5-2650 v4 servers costing 9,000 euros for a penny?</font></font></a></div>
      
    </div>
<section class="more-articles-navigation-panel js-more-articles-navigation-panel">
<h4>More articles:</h4>
<nav class="list-of-articles-container js-list-of-articles-container"><ul class="list-of-pages js-list-of-pages">
<li><a href="../en497126/index.html">Backlog scoring and prioritization techniques</a></li>
<li><a href="../en497132/index.html">#SaveFirst Initiative to Support Socially Important Projects</a></li>
<li><a href="../en497136/index.html">“Save Concord” or a report from the tests of the Russian radar system for searching for foreign objects on the runway</a></li>
<li><a href="../en497140/index.html">Decryption of data in the CAN bus VW Polo sedan</a></li>
<li><a href="../en497142/index.html">How we added Harmony OS support to the inDriver Android application</a></li>
<li><a href="../en497146/index.html">Applied cryptography. How we restored bitcoins for 300 thousand dollars</a></li>
<li><a href="../en497148/index.html">Creating a desktop application using Golang and Fyne</a></li>
<li><a href="../en497152/index.html">Where Product Heart Lives: Metrics for Measuring Happiness</a></li>
<li><a href="../en497154/index.html">Videos of all reports from eight Ontico conferences</a></li>
<li><a href="../en497156/index.html">Webinar "Artificial Intelligence in Questions and Answers"</a></li>
</ul></nav>
</section><br />
<a href="../../allArticles.html"><strong>All Articles</strong></a>
<script src="../../js/main.js"></script>

<!-- Yandex.Metrika counter -->
<script type="text/javascript" >
  (function (d, w, c) {
      (w[c] = w[c] || []).push(function() {
          try {
              w.yaCounter63335242 = new Ya.Metrika({
                  id:63335242,
                  clickmap:true,
                  trackLinks:true,
                  accurateTrackBounce:true,
                  webvisor:true
              });
          } catch(e) { }
      });

      var n = d.getElementsByTagName("script")[0],
          s = d.createElement("script"),
          f = function () { n.parentNode.insertBefore(s, n); };
      s.type = "text/javascript";
      s.async = true;
      s.src = "https://mc.yandex.ru/metrika/watch.js";

      if (w.opera == "[object Opera]") {
          d.addEventListener("DOMContentLoaded", f, false);
      } else { f(); }
  })(document, window, "yandex_metrika_callbacks");
</script>
<noscript><div><img src="https://mc.yandex.ru/watch/63335242" style="position:absolute; left:-9999px;" alt="" /></div></noscript>

<!-- Google Analytics -->
  <script>
    window.ga = function () { ga.q.push(arguments) }; ga.q = []; ga.l = +new Date;
    ga('create', 'UA-134228602-13', 'auto'); ga('send', 'pageview')
  </script>
  <script src="https://www.google-analytics.com/analytics.js" async defer></script>

</section>

<footer class="page-footer">
  <div class="page-footer-legal-info-container page-footer-element">
    <p>
      Geek Week | <span class="page-footer-legal-info-year js-page-footer-legal-info-year">2020</span>
    </p>
  </div>
  <div class="page-footer-counters-container page-footer-element">
    <a class="page-footer-counter-clustrmap" href='#'  title='Visit tracker'><img src='https://clustrmaps.com/map_v2.png?cl=698e5a&w=271&t=t&d=i62cJ2037o_BACd40gCrIso3niu0Sjx2sDFYJkeYdRk&co=3a3a3a&ct=ffffff'/></a>
  </div>
</footer>
  
</body>

</html>